• The incidence of cutaneous malignant melanoma continues to rise worldwide but there is evidence of a levelling of mortality in some groups as patients are presenting earlier.
• Incisional biopsy of a melanoma does not in general alter the prognosis adversely but may lead to problems in interpreting the histology.
• The main treatment for primary melanoma of the skin is surgical excision.
• There is good evidence from RCTs that the narrower margins used over the past 20 years are safe.
• All the treatments used for LM and LMM have poor evidence to support them and well-organised RCTs are needed in this area. Surgical excision probably represents the best treatment on current evidence.
• Elective lymph node dissection of uninvolved nodes does not improve prognosis in most patient groups.
• SLNB is a useful staging tool but there is no evidence as yet that it improves overall survival.
• Interferons used as adjuvant treatments can benefit some patient groups with MM, but further information is needed to clarify the optimum usage of this treatment.
analysis of the high-dose regimen, the estimated 11. cost per life-year gained was US$13 700 over 35 years and US$32 600 over 10 years; the estimated cost of low-dose treatment per life- 12. year gained was estimated to be US$1700 over a lifetime and US$6600 over 10 years. These costs were thought to be comparable to many 13. other oncological treatments.51,52
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.